Pre-made Varisacumab benchmark antibody ( Whole mAb, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-613
Pre-Made Varisacumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Varisacumab (GNR 011), a biosimilar of bevacizumab [see Adis Insight Drug profile 800008086] is under development with International Biotech Center Generium (IBC Generium), for the treatment of various types of cancer, including colorectal, non-small cell lung, glioblastoma and breast cancer, and ophthalmic conditions.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Varisacumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II/III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS|
|Conditions Active||Breast cancer;Colorectal cancer;Eye disorders;Glioblastoma;Non-small cell lung cancer|